Skip to main content
. 2023 Jul 22;23:369. doi: 10.1186/s12872-023-03381-x

Table 3.

Clinical, laboratory and imaging data of hypertension patients among different antihypertensive targets

Variables Intensive Treatment (n = 85) Standard Treatment (n = 214) P value a
Pre-treatment Post-treatment Pre-treatment Post-treatment
Systolic pressure, mmHg 133.00 [123.00, 147.00] 112.00 [106.00, 117.00] 134.00 [126.00, 151.00] 130.00 [125.00, 134.00]  < 0.001
Diastolic pressure, mmHg 79.00 [71.00, 87.00] 73.00 [67.00, 80.00] 78.00 [70.00, 86.00] 76.00 [69.25, 83.00] 0.103
Heart rate, bpm 72.00 [66.00, 78.25] 72.00 [66.00, 78.00] 72.00 [69.00, 78.00] 74.00 [68.00, 80.00] 0.398
Laboratory Findings
 Venous blood glucose, mmol/L 5.00 [4.69, 5.94] 5.30 [5.02, 5.90] 5.20 [4.83, 6.03] 5.28 [4.93, 6.16] 0.778
 Serum creatinine, μmol/L 73.80 [61.05, 86.00] 74.20 [65.47, 92.17] 70.30 [57.35, 86.90] 69.40 [58.20, 90.00] 0.061
 Blood urea nitrogen, mmol/L 5.30 [4.51, 6.12] 5.78 [4.57, 7.18] 5.30 [4.45, 6.50] 5.70 [4.60, 7.13] 0.857
 Uric acid, μmol/L 353.70 [305.70, 437.00] 379.10 [314.22, 449.78] 346.10 [266.75, 430.40] 351.40 [277.60, 425.10] 0.011
 Calcium ion, mmol/L 2.24 [2.16, 2.32] 2.25 [2.17, 2.34] 2.27 [2.16, 2.36] 2.25 [2.19, 2.34] 0.801
 Potassium ion, mmol/L 3.95 [3.74, 4.12] 3.94 [3.72, 4.15] 3.87 [3.64, 4.16] 3.95 [3.70, 4.14] 0.972
 Sodium ion, mmol/L 140.75 [138.70, 142.35] 140.00 [138.00, 142.00] 140.40 [138.60, 141.80] 140.60 [138.80, 142.20] 0.248
 Total cholesterol, mmol/L 4.18 [3.68, 4.88] 3.67 [3.28, 4.27] 4.56 [3.71, 5.17] 4.16 [3.32, 5.02] 0.003
 High density lipoprotein, mmol/L 1.17 [1.01, 1.34] 1.09 [0.92, 1.27] 1.14 [0.94, 1.40] 1.13 [0.93, 1.30] 0.435
 Low density lipoprotein, mmol/L 2.50 [2.12, 3.12] 2.13 [1.66, 2.57] 2.70 [2.14, 3.24] 2.42 [1.74, 3.18] 0.014
 Triglyceride, mmol/L 1.33 [1.05, 1.80] 1.16 [0.84, 1.65] 1.42 [0.99, 2.01] 1.29 [0.92, 1.95] 0.197
 Creatine kinase, U/L 81.00 [66.25, 125.62] 96.00 [73.25, 131.25] 89.00 [68.00, 135.25] 94.00 [66.00, 137.00] 0.841
 Creatine kinase-MB, U/L 12.00 [10.00, 15.50] 13.00 [10.00, 20.00] 12.00 [8.00, 15.75] 13.00 [10.00, 17.00] 0.347
 Lactate dehydrogenase, U/L 190.50 [170.25, 218.75] 190.00 [167.00, 227.75] 189.00 [167.25, 220.00] 186.00 [164.00, 211.00] 0.453
 Cardiac troponin I, pg/mL 3.90 [1.90, 9.15] 3.60 [1.90, 12.70] 3.30 [1.90, 8.90] 3.70 [1.90, 10.10] 0.958
 Pro-brain natriuretic peptide, pg/mL 79.05 [40.47, 266.00] 58.10 [24.47, 261.00] 111.00 [67.75, 312.25] 99.70 [59.90, 408.50] 0.014
Echocardiography
 Ascending aorta diameter, mm 33.00 [28.25, 34.00] 32.00 [30.00, 34.00] 32.00 [29.00, 35.00] 33.00 [30.00, 35.00] 0.177
 Left atrial diameter, mm 33.00 [30.00, 36.00] 34.00 [31.50, 37.50] 34.00 [31.00, 37.00] 35.00 [31.00, 39.00] 0.324
 Left ventricular diameter, mm 43.00 [41.00, 46.00] 45.00 [41.50, 48.00] 44.00 [41.00, 47.25] 44.50 [42.00, 48.00] 0.957
 Ventricular septal thickness, mm 11.00 [10.00, 12.00] 11.00 [10.00, 12.00] 11.00 [10.00, 12.00] 11.00 [10.00, 12.00] 0.855
 Pulmonary artery diameter, mm 24.00 [23.00, 25.50] 24.00 [22.00, 25.75] 24.00 [23.00, 26.00] 24.00 [21.00, 26.00] 0.881
 LVEF, (%) 66.00 [61.50, 71.00] 65.00 [59.00, 69.00] 65.00 [61.00, 70.00] 63.00 [59.00, 68.00] 0.662
 Severe valve regurgitation, n (%) 13 (15.29) 26 (30.59) 39 (18.22) 77 (35.98) 0.453
 Severe valve calcification, n (%) 12 (14.12) 17 (20.00) 31 (14.49) 46 (21.50) 0.898
Complications
 Diabetes, n (%) 15 (17.65) 24 (28.24) 38 (17.76) 50 (23.36) 0.464
 Hyperlipidemia, n (%) 13 (15.29) 22 (25.88) 45 (21.03) 62 (28.97) 0.694
Treatments
 Single-drug, n (%) 28 (32.94) 84 (39.25) 0.565
 Two-drug, n (%) 39 (45.88) 92 (42.99)
 Multi-drug, n (%) 18 (21.18) 38 (17.76)
Clinical outcomes 21 (24.71) 86 (40.19) 0.017

NA Not available. P values < 0.05 are written in italics

Values shown are mean ± SD, median (interquartile range [IQR]) or n (%). P values were calculated by chi-squared test, Fisher’s exact test, t test, or Mann–Whitney U test, as appropriate

Abbreviations: n Number, LVEF Left ventricular ejection fraction

aStatistical difference between the intensive group and standard group after treatment